News
3 Reasons Spark Therapeutics Is a Buy After Its Crash
After Spark Therapeutics and competitor BioMarin Therapeutic (NASDAQ: BMRN) updated investors on the progress that they're making developing competing gene therapies for hemophilia, investors....
3 Top Healthcare Stocks to Buy in December
If you're looking to put some healthcare stocks in your portfolio this holiday season, then it could be a very good time to consider Welltower Inc (NYSE: HCN), Geron Corporation (NASDAQ: GERN),....
ASH 2017: CAR-T Wallops Blood Cancer
The American Society of Hematology (ASH) annual meeting this past weekend was chock-full of excitement, including an unexpected snowstorm in Atlanta and a slew of game-changing non-Hodgkin....
What Happened in the Stock Market Today
Stocks moved higher on Monday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) closing at record highs.Data source: Yahoo! Finance.Telecom and tech....
What's Causing Juno Therapeutics Shares to Tumble 11.9% Today
After the company presented data on its chimeric antigen receptor T-cell therapy (CAR-T), JCAR017, at the annual American Society of Hematology conference over the weekend, Juno Therapeutics....
Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a biotech developing gene therapies, fell hard this morning after the company reported hemophilia trial data that bodes well for rival BioMarin....
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biotech rising like a phoenix from the ashes of Belviq's commercial flop, rose 10.6% in November, according to data from S&P Global....
The 3 Marijuana Stocks With the Most Cash on Their Balance Sheets
There aren't too many industries that can hold a candle to the returns of cryptocurrencies these days, but the marijuana industry isn't going down without a fight. Marijuana stocks certainly have....
Why Opko Health Stock Stumbled in November
Shares of Opko Health (NASDAQ: OPK) had another poor showing in November, with its stock shedding a whopping 19.5% of its value last month, according to data from S&P Global Market....
Is Now the Perfect Time to Buy Juno Therapeutics Stock?
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage oncology company, continued its unrelenting rally this year by tacking on another $5 billion to its market cap in November, according to data....
Cantel Medical Corp. Keeps Pace on Its Goal
Cantel Medical (NYSE: CMD) reported results for the first quarter, posting double-digit revenue and earnings growth to start its fiscal year. It's hard to ask for more from the medical-supply....
What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's predominantly grown through acquisitions and drug-price increases over the years, surged as much as 11% by 3 p.m. EST....
Cantel Medical (CMD) Q1 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Cantel Medical (NYSE: CMD) Q1 2018 Earnings Conference CallDec. 7, 2017 11:00 a.m. ETOperatorContinue readingSource: Fool.com
A Game-Changing Breakthrough Could Be Coming for Hemophilia Patients
Patients diagnosed with hemophilia B suffer a lifetime of treatment, but that could change based on recently reported data from an early stage trial Pfizer (NYSE: PFE) and Spark Therapeutics....
Why Sage Therapeutics Gained 70% Today
Shares of Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biotech, took flight today, after the company announced positive mid-stage trial results for its moderate-to-severe major depressive....
What Happened in the Stock Market Today
Stocks moved higher on Thursday, with the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) both up a little more than a quarter percentage point.Data source:....
Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday
Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose over 41% today after larger peer Sage Therapeutics (NASDAQ: SAGE) reported positive top-line results for one of its....
Is Exelixis, Inc. a Buy?
Yes.I know I'm breaking all the rules about building up suspense, etc. But I think Exelixis (NASDAQ: EXEL) is a buy right now. I think the stock will go higher over the next few years. Don't just....
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug....
Here's Why bluebird bio's Shares Soared 24% in November
After bluebird bio (NASDAQ: BLUE) updated investors on the presentations it will be making at a key industry conference soon, its shares jumped 24.2% in November, according to S&P Global....
Why Immunomedics, Inc. Is Soaring Today
After Immunomedics (NASDAQ: IMMU) shared some positive clinical data with investors, shares of the clinical-stage biotech focused on cancer rose 17% as of 3:10 p.m. EST on Wednesday.Immunomedics....
Why DaVita Inc. Jumped Higher Today
DaVita (NYSE: DVA) is up 12.8% at 12:35 p.m. EST after announcing that it's selling its medical group to UnitedHealth Group's (NYSE: UNH) health services business Optum for $4.9 billion.....
Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13%....
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according....
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....